News
ITCI
69.72
+3.55%
2.39
Weekly Report: what happened at ITCI last week (0318-0322)?
Weekly Report · 3d ago
Buy Rating Affirmed on Intra-Cellular Therapies Ahead of Key Phase 3 Results and Strategic Leadership Enhancements
TipRanks · 03/21 06:45
Intra-Cellular Therapies Announces Executive Leadership Changes
TipRanks · 03/19 13:02
Intra-Cellular Therapies promotes Michael Halstead to President
Intra-Cellular Therapies promotes Michael Halstead to the position of President. Halstead is currently serving as Executive Vice President and General Counsel. Senior Vice President Larry Hineline will be retiring after more than 20 years of service. Intra- cellular therapeutic, Inc. (ITCI)
Seeking Alpha · 03/19 12:43
Intra-Cellular Therapies Chief Financial Officer Larry Hineline to Retire
Intra-Cellular Therapies' long-time finance chief, Larry Hineline, is retiring after more than two decades with the company. Hineline has been chief financial officer since June 2002. The biopharmaceutical company has launched an external search for a successor.
Dow Jones · 03/19 12:43
*Intra-Cellular Therapies Initiated External Search for a New Chief Fincl Officer >ITCI
Dow Jones · 03/19 12:32
*Intra-Cellular Therapies: Hineline Has Agreed to Remain Through the Process to Ensure Smooth Transition >ITCI
Dow Jones · 03/19 12:32
*Intra-Cellular Therapies: Chief Fincl Officer Larry Hineline Will Be Retiring >ITCI
Dow Jones · 03/19 12:31
*Intra-Cellular Therapies Promotes Michael Halstead, J.D. to the Position of Pres >ITCI
Dow Jones · 03/19 12:31
Press Release: Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Intra-Cellular Therapies, Inc. Announced the promotion of Michael Halstead, J.D. To the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. The biopharmaceutical company also announced that senior vice president and chief financial officer, Larry Hineline, will be retiring.
Dow Jones · 03/19 12:30
Weekly Report: what happened at ITCI last week (0311-0315)?
Weekly Report · 03/18 09:25
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Intra-Cellular Therapies has reduced its cash burn by 54% over the last year. The company is burning through its cash to fund its growth. Its revenue growth of 86% is encouraging, and the company has no debt. Intra- cellular therapies had a cash runway of 4.0 years to reach breakeven, according to analyst forecasts. We believe the company is in a good position to continue to grow.
Simply Wall St · 03/17 13:49
Intra-Cellular Therapies Is On Fire
Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand its use to treat Major Depressive Disorder. In 2023, there were 36,000 psychiatrists prescribing the drug to schizophrenia and bipolar depression patients in the US.
Seeking Alpha · 03/11 23:11
Weekly Report: what happened at ITCI last week (0304-0308)?
Weekly Report · 03/11 09:24
Noteworthy Thursday Option Activity: ULTA, SCCO, ITCI
NASDAQ · 03/07 20:18
Intra-Cellular Therapies: Statement of changes in beneficial ownership of securities
Press release · 03/06 03:03
Buy Rating Affirmed for Intra-Cellular Therapies Amid Positive Outlook for Caplyta’s MDD Trial
TipRanks · 03/05 06:26
Weekly Report: what happened at ITCI last week (0226-0301)?
Weekly Report · 03/04 09:25
Outperform Rating for Intra-Cellular Therapies Amidst Strong Caplyta Sales and Promising Clinical Prospects
TipRanks · 03/01 06:13
S&P 500 Futures Flat In Premarket Trading; Domino's Pizza, Alpha Metallurgical Rscs Lead
U.S. Stock markets set to open in two hours. Domino's Pizza Inc. Was up 7.1% in pre-market trading. S&P 500 futures were down 0.04% in early trading. Stocks in Asia were mixed overnight. Brent crude oil and gold futures are down in commodities news.
Barron‘s · 02/26 12:31
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.